Crizotinib
Sign in to save this workspacePrimary targets: ALK, ROS_ROS1 · FDA status: FDA Approved
Selectivity scorecard
KISS
91.39
Gini
0.581
CATDS
0.009
Computed from wild-type kinome inhibition at 1 μM. Gini reproduces the published values within tolerance; KISS and CATDS are computed but pending reconciliation with the paper's reference code.
Polypharmacology radar
Top 20 strongest-inhibited wild-type kinases for Crizotinib. Strongest target: EPHA6 at 100.0% inhibition.
Accessible data table
| Rank | Target | Inhibition % | Residual activity % |
|---|---|---|---|
| 1 | EPHA6 | 100.0% | 0.0% |
| 2 | ROS_ROS1 | 100.0% | 0.0% |
| 3 | RON_MST1R | 99.8% | 0.2% |
| 4 | LIMK1 | 98.9% | 1.1% |
| 5 | JAK2 | 98.7% | 1.3% |
| 6 | TRKB | 98.5% | 1.5% |
| 7 | TYK1_LTK | 98.3% | 1.7% |
| 8 | HPK1_MAP4K1 | 97.9% | 2.1% |
| 9 | ALK | 97.7% | 2.3% |
| 10 | MUSK | 97.7% | 2.3% |
| 11 | TRKC | 97.3% | 2.7% |
| 12 | AXL | 97.1% | 2.9% |
| 13 | ABL1 | 97.0% | 3.0% |
| 14 | LCK | 96.8% | 3.2% |
| 15 | EPHB1 | 96.8% | 3.2% |
| 16 | C_MET | 96.7% | 3.3% |
| 17 | ARK5_NUAK1 | 96.4% | 3.6% |
| 18 | EPHA2 | 96.0% | 4.0% |
| 19 | TRKA | 95.8% | 4.2% |
| 20 | FAK_PTK2 | 95.7% | 4.3% |
Selectivity landscape
Where Crizotinib sits in the 92-drug selectivity landscape (KISS vs Gini). The highlighted point is Crizotinib.
Atlas insights for Crizotinib
Pathway-space view of what this drug actually does, drawn from the Pathway Atlas.
On-target vs off-target shadow
On-target0%
Off-target100%
Ghost (2nd-order)0%
| Pathway | Composition | Total |Π| |
|---|---|---|
| ADIPOGENESIS | 2894.19 | |
| ALLOGRAFT_REJECTION | 9752.38 | |
| ANDROGEN_RESPONSE | 1405.54 | |
| ANGIOGENESIS | 1502.50 | |
| APICAL_JUNCTION | 9109.49 | |
| APICAL_SURFACE | 1025.67 | |
| APOPTOSIS | 6329.09 | |
| BILE_ACID_METABOLISM | 926.38 | |
| CHOLESTEROL_HOMEOSTASIS | 1202.01 | |
| COAGULATION | 1195.43 | |
| COMPLEMENT | 5694.69 | |
| DNA_REPAIR | 1679.91 | |
| E2F_TARGETS | 4000.78 | |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 1822.43 | |
| ESTROGEN_RESPONSE_EARLY | 3233.88 | |
| ESTROGEN_RESPONSE_LATE | 2999.54 | |
| FATTY_ACID_METABOLISM | 739.61 | |
| G2M_CHECKPOINT | 4352.92 | |
| GLYCOLYSIS | 2689.26 | |
| HEDGEHOG_SIGNALING | 997.00 | |
| HEME_METABOLISM | 2158.70 | |
| HYPOXIA | 4182.10 | |
| IL2_STAT5_SIGNALING | 3661.12 | |
| IL6_JAK_STAT3_SIGNALING | 6495.40 | |
| INFLAMMATORY_RESPONSE | 5290.61 | |
| INTERFERON_ALPHA_RESPONSE | 893.79 | |
| INTERFERON_GAMMA_RESPONSE | 7244.00 | |
| KRAS_SIGNALING_DN | 958.57 | |
| KRAS_SIGNALING_UP | 3434.46 | |
| MITOTIC_SPINDLE | 5986.05 | |
| MTORC1_SIGNALING | 3808.45 | |
| MYC_TARGETS_V1 | 2859.95 | |
| MYC_TARGETS_V2 | 910.13 | |
| MYOGENESIS | 2889.61 | |
| NOTCH_SIGNALING | 215.03 | |
| OXIDATIVE_PHOSPHORYLATION | 1167.52 | |
| P53_PATHWAY | 3735.47 | |
| PANCREAS_BETA_CELLS | 269.26 | |
| PEROXISOME | 1067.82 | |
| PI3K_AKT_MTOR_SIGNALING | 9119.10 | |
| PROTEIN_SECRETION | 1696.07 | |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 509.13 | |
| SPERMATOGENESIS | 1530.90 | |
| TGF_BETA_SIGNALING | 1762.50 | |
| TNFA_SIGNALING_VIA_NFKB | 4527.56 | |
| UNFOLDED_PROTEIN_RESPONSE | 1392.88 | |
| UV_RESPONSE_DN | 4866.48 | |
| UV_RESPONSE_UP | 4009.65 | |
| WNT_BETA_CATENIN_SIGNALING | 1769.28 | |
| XENOBIOTIC_METABOLISM | 1846.55 |
Hallmarks-of-Cancer reach
Anti-tumor matches — the "ideal patient" search
| Sample | Cancer type | cos to ideal |
|---|---|---|
| EPT0291 | EPN | 0.835 |
| SRR23303752 | — | 0.831 |
| SRR10899984 | — | 0.826 |
| TCGA-CF-A5U8-01A-11R-A28M-07 | — | 0.818 |
| aMVAC.P_005_TURBT_S223 | — | 0.816 |
Annotations
Sign in to read and post annotations.
Loading…